Brief: Biocryst Pharmaceuticals - On March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's
11/03/2025 10:30
March 11 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST PHARMACEUTICALS INC - ON MARCH 10, FILES PATENT INFRINGEMENT LAWSUIT AGAINST ANNORA AND OTHER CO'S BIOCRYST PHARMACEUTICALS INC - SEEKS TO BLOCK FDA APPROVAL OF GENERIC ORLADEYO UNTIL PATENT EXPIRATION Source text: [ID:n0001171843-25-001383] Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026